nChroma Bio

health AI? biotech? medtech? (biotech/genetic medicines)

Visit website LinkedIn ↗

StageEarly Stage VC

Raised$75 million

Founded2024

Employees58

LocationBoston, MA

About

nChroma Bio is a clinical-stage genetic medicines company developing engineered epigenetic silencers to overcome the limitations of existing therapies and enable next-generation genomic medicines. By combining in vivo delivery and gene-regulating technologies, nChroma is designing optimal solutions to deliver precise, potent and durable treatments for patients with high unmet needs. nChroma’s lead candidate, CRMA-1001, is a clinical-stage, liver-directed epigenetic silencer in development as a potential functional cure for chronic hepatitis B. Guided by a world-class team at the forefront of genetic medicine, founded by renowned pioneers in the field, and supported by top-tier investors, nChroma is redefining targeted in vivo genetic medicine with the initial goal of treating diseases affecting the liver, blood, cardiovascular and central nervous systems.

Product

Value proposition: Developing targeted in vivo genetic medicines with disease-first design to deliver potent, durable treatments that address specific biological drivers of disease and unmet need.

Founders

David Liu — Founder/Pioneer
Keith Joung — Founder/Pioneer

Products

targeted in vivo genetic medicinesdelivery technologies for genetic cargoes

Key features

targeted in vivo deliverytailored genetic cargoeslong-lasting genetic medicinesdisease-first therapeutic design

Technologies

in vivo deliverygenetic cargo designdelivery vectorsprecision medicine

Investors

Cormorant Asset ManagementARCH Venture PartnersAtlas VentureNewpath Partners5AM VenturesDCVC BioF-Prime CapitalGV (Google Ventures)Janus Henderson InvestorsMubadala CapitalOmega FundsSixth StreetSofinnova PartnersT. Rowe PriceWellington ManagementAlexandria Venture InvestmentsCasdin CapitalMenlo VenturesWilson Sonsini Goodrich & Rosati

News

nChroma Bio · 2024-12-11T00:00:00.000Z
nChroma Bio 2026 Company Profile: Valuation, Funding & Investors · 2025-02-06T00:00:00.000Z
Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines - BioSpace · 2024-12-11T12:40:02.000Z
nChroma Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of Epigenetic Silencer CRMA-1001 for Chronic Hepatitis B · 2026-01-28T12:00:00.000Z
nChroma Bio sheds staff in research reorganization · 2025-11-12T22:31:04.000Z

Browse similar startups

Related startups

Neoclease — Boston, MA
Neuronity — Mansfield, MA
Nine Diagnostics — Cambridge, MA
Novastra Therapeutics — Boston, MA
NxtCure — Boston, MA
OncoSys AI — Cambridge, MA
Oral Genome — Carlsbad, CA
Phinomics — San Carlos, CA
Response Pharmaceuticals — Mclean, VA
Riboway Therapeutics — Cambridge, MA
Sarcomatrix — Reno, NV
Senvera Therapeutics, Inc. A Curie.Bio Company — Boston, MA

Profile updated Jul 29, 2026. Sources: nchromabio.com, linkedin.com